Fig. 7: Antitumor evaluation of DNA-PAE@BAY-876 in vivo. | Nature Communications

Fig. 7: Antitumor evaluation of DNA-PAE@BAY-876 in vivo.

From: Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer

Fig. 7

a Schematic diagram of treatment schedule of DNA-PAE@BAY-876 nanoassemblies on 4T1 tumor-bearing mice. b Visual comparison of tumors from Balb/c mice after different treatment. c In vivo bioluminescence images on the tumor progression in Balb/c mice in different groups. d Tumor volume changes after different treatment. e Final tumor weight in different groups at the end of the 21 days period. I NC, (II) PAE, (III) aptCTLA-4, (IV) aptPD-L1, (V) BAY-876, (VI) DNA-PAE, (VII) DNA-PAE@BAY-876. f Body weight changes of Balb/c mice in different groups during treatment. g–h TUNEL and H&E staining of tumor samples with five mice per group. i–k ELISA assay of glucose, lactic acid and UDP-GlcNAc abundance in tumor samples. In vivo histological experiments in panels g–h were repeated three times independently with similar results. Data are presented as mean values ± SEM (n = 5 mice for panels d–f, n = 3 mice for panels i and k, n = 4 mice for panel j). Statistical analysis was carried out via two-way ANOVA method. Source data are provided as a Source Data file.

Back to article page